186046-78-6

Basic information

• Product Name: (4-N-(BENZHYDRYLOXYCARBONYL)CYTOSINE)-1-ACETIC ACID
• Synonyms: (4-N-(BENZHYDRYLOXYCARBONYL)CYTOSINE)-1-ACETIC ACID ;(4-Benzhydryloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-acetic acid;(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic;2-(4-(((Benzhydryloxy)carbonyl)aMino)-2-oxopyriMidin-1(2H)-yl)acetic acid;2-[4-(benzhydryloxycarbonylamino)-2-oxopyrimidin-1-yl]acetic acid
• CAS NO: 186046-78-6
• Molecular Formula: C₂₀H₁₇N₃O₅
• Molecular Weight: 379.36608
• Mol File: 186046-78-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.33 g/cm³
• Refractive Index: 1.635
• Storage Temp.: 2-8°C
• PKA: 2.95±0.10(Predicted)
• CAS DataBase Reference: (4-N-(BENZHYDRYLOXYCARBONYL)CYTOSINE)-1-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (4-N-(BENZHYDRYLOXYCARBONYL)CYTOSINE)-1-ACETIC ACID(186046-78-6)
• EPA Substance Registry System: (4-N-(BENZHYDRYLOXYCARBONYL)CYTOSINE)-1-ACETIC ACID(186046-78-6)

Safety Data

• Hazardous Substances Data: 186046-78-6(Hazardous Substances Data)

Usage

General Description

"(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic acid" is a chemical compound that consists of a cytosine derivative linked to an acetic acid molecule. The benzhydryloxycarbonyl group attached to the cytosine molecule is a protecting group widely used in organic synthesis to block reactive functional groups and prevent unwanted reactions, while the acetic acid group acts as a carboxylic acid derivative. (4-N-(BENZHYDRYLOXYCARBONYL)CYTOSINE)-1-ACETIC ACID may be used in peptide synthesis or drug development as a building block or intermediate. Its precise application and potential uses depend on the specific goals of the research or synthesis project.

InChI:InChI=1/C20H17N3O5/c24-17(25)13-23-12-11-16(21-19(23)26)22-20(27)28-18(14-7-3-1-4-8-14)15-9-5-2-6-10-15/h1-12,18H,13H2,(H,24,25)(H,21,22,26,27)

Upstream product

• 623145-62-0 benzyl (4-N-(benzhydryloxycarbonyl)cytosine)-1-acetate 
• 211321-08-3 cytosine-1-benzylacetic acid 
• 91-01-0 1,1-Diphenylmethanol 

Downstream Products

• 620628-74-2 N-[2-(benzothiazole-2-sulfonylamino)-ethyl]-N-{[4-N-(benzhydryloxycarbonyl)-cytosin-1-yl]-acetyl}-glycine ethyl ester 
• 623145-54-0 N-(2-azidoethyl)-N-[4-N-(benzhydryloxycarbonyl)cytosine-1-acetyl]glycine 
• 623145-46-0 benzyl N-(2-azidoethyl)-N-[4-N-(benzhydryloxycarbonyl)cytosine-1-acetyl]glycinate 
• 623145-66-4 (1-{[(2-azido-ethyl)-(benzylcarbamoyl-methyl)-carbamoyl]-methyl}-2-oxo-1,2-dihydro-pyrimidin-4-yl)-carbamic acid benzhydryl ester 
• 620629-08-5 1-(benzothiazole-2-sulfonyl)-4-{[4-N-(benzhydryloxycarbonyl)cytosin-1-yl]acetyl}piperazin-2-one 
• 620629-13-2 1-(5-chloro-benzothiazole-2-sulfonyl)-4-{[4-N-(benzhydryloxycarbonyl)-cytosin-1-yl]-acetyl}-piperazin-2-one 
• 568585-80-8 N-{[4-N-(Benzhydryloxycarbonyl)-cytosin-1-yl]-acetyl}-N-[2-(2-nitro-benzenesulfonylamino)-ethyl]-glycine ethyl ester 
• 568585-92-2 4-{[4-N-(Benzhydryloxycarbonyl)-cytosin-1-yl]-acetyl}-1-(2-nitro-benzenesulfonyl)-piperazin-2-one 
• 568587-20-2 4-{[4-N-(Benzhydryloxycarbonyl)-cytosin-1-yl]acetyl}-1-(4-chloro-2-nitro-benzenesulfonyl)-piperazin-2-one 
• 568586-04-9 4-{[4-N-(Benzhydryloxycarbonyl)-cytosin-1-yl]acetyl}-1-(4-fluoro-2-nitro-benzenesulfonyl)-piperazin-2-one 
• 1372649-93-8 C₅₀H₅₆N₆O₁₀ 

Relevant articles and documents

Nucleic acid medicine delivery system and application thereof

The invention discloses a nucleic acid medicine delivery system and application thereof. The system consists of a neutral base lipid carrier and metal salt, wherein the structure of the neutral base lipid carrier is shown as a formula I. In addition, the delivery system provided by the invention also comprises metal salt. The experiment proves that through the existence of metal ion, the silent activity of the nucleic acid medicine can be effectively improved; the effective transportation of the nucleic acid medicine in the cells and in the body can be realized. The chemical modification methods such as D,L-isonucleoside modification, deoxyinosine modification, peptide conjugation modification and phosphorylation modification are jointly used for nucleic acid delivery system study; the advantages and rules of the nucleic acid delivery in a composite modification mode are sufficiently explored; the modification strategies are used in the nucleic acid medicine study. Study proves that the products obtained through chemical modification are more applicable to the system; in addition, the advantages of stable physicochemical properties, good bioactivity and good membrane permeability and the like are realized. The nucleic acid medicine delivery system provided by the invention has wide application prospects in the gene treatment field. The formula is shown in the description.

Azidopeptide Nucleic Acid. An Alternative Strategy for Solid-Phase Peptide Nucleic Acid (PNA) Synthesis

(Equation presented) A practical and efficient method for PNA synthesis using an azide group to mask the N-terminus is reported. The deprotection was carried out in 5 min, while couplings were complete within 60 min. The near neutral conditions of the pho